Veerhealth Care secured a ₹1.11 crore repeat order for healthcare products and issued warrants worth ₹20.25 each. Promoters are participating, aiming to boost book value and fund expansion. The company also provided income guidance for FY27 and FY28.
Veerhealth Care Secures Repeat Order, Issues Warrants for Growth
₹1.11 crore (Repeat Order)
1,00,00,000 warrants issued
Reader Takeaway: Repeat order signals client trust; warrant issue aims for expansion, but projections carry risks.
What just happened
Veerhealth Care has received a repeat order valued at ₹1.11 crore for its Hair Care and Oral Care products. This order is expected to be completed within 45 days. The company also approved the allotment of 1,00,00,000 warrants at ₹20.25 per warrant, with promoters subscribing to 45,37,000 of these. This preferential issue is intended to raise capital for business expansion and is expected to increase the company's book value per share, which was ₹11.46 as of FY26.
Why this matters
The repeat order indicates customer satisfaction and provides short-term revenue visibility. The capital raised through warrants, with significant promoter participation, signals confidence and aims to fund future growth. This move is expected to bolster the company's financial standing and support its ambitious income projections.
The backstory
Veerhealth Care specializes in manufacturing pure vegetarian toothpaste and 'Ayuveer' herbal/ayurvedic products. The company has highlighted its USFDA plant clearance as a key operational differentiator. It is also in discussions with a major hotel amenities supplier for a potential partnership.
What changes now
The newly acquired order will contribute to immediate revenue. The capital from the warrant issue will be used for business expansion, potentially accelerating growth towards the projected income figures. The company has provided income guidance of ₹105 crore for FY27 and ₹156 crore for FY28, with a projected PAT of ₹5-6 crore and ₹9-10 crore respectively.
Risks to watch
Management has cautioned that the financial projections are subject to various uncertainties, including government actions, political developments, and technological risks. Investors should monitor the execution of current orders and the progress of ongoing expansion plans.
Peer comparison
As a small-cap entity, Veerhealth Care operates in a competitive market for healthcare and oral care products. Its USFDA plant clearance is a notable operational credential within its segment.
Context metrics (time-bound)
The repeat order has an execution timeline of 45 days. Financial guidance is provided for FY27 (₹105 crore income) and FY28 (₹156 crore income). The book value per share stood at ₹11.46 as of FY26.
What to track next
Investors should watch for the successful completion of the current order, the finalization of the potential partnership with the hotel amenities supplier, and the company's performance against its FY27 and FY28 income and PAT guidance.